Tokyo Tape
Sign in
← Kaken Pharmaceutical

Quarterly report · Q2

4521.TEDINET S100PKU1
Period2022-04-01 → 2022-09-30
Filed2022-11-11
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 46
MetricValuePeriodScopeSource row
Revenue¥36.8bn2022-04-01 → 2022-09-30Cons.Net sales
Revenue¥76.0bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥37.6bn2021-04-01 → 2021-09-30Cons.Net sales
Operating income¥8.2bn2022-04-01 → 2022-09-30Cons.Operating income
Operating income¥9.0bn2021-04-01 → 2021-09-30Cons.Operating income
Ordinary income¥8.6bn2022-04-01 → 2022-09-30Cons.Ordinary income
Ordinary income¥17.5bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥9.3bn2021-04-01 → 2021-09-30Cons.Ordinary income
Profit before tax¥8.2bn2022-04-01 → 2022-09-30Cons.Income before income taxes
Profit before tax¥9.4bn2021-04-01 → 2021-09-30Cons.Income before income taxes
Net income (owners)¥6.0bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥9.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥6.7bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent
Net income¥6.0bn2022-04-01 → 2022-09-30Cons.Profit loss
Net income¥6.7bn2021-04-01 → 2021-09-30Cons.Profit loss
Total assets¥167.3bnat 2022-09-30Cons.Assets
Total assets¥165.2bnat 2022-03-31Cons.Assets
Total assets¥165.6bnat 2021-09-30Cons.Total assets (5-year summary)
Total liabilities¥26.9bnat 2022-09-30Cons.Liabilities
Total liabilities¥26.9bnat 2022-03-31Cons.Liabilities
Net assets / equity¥140.4bnat 2022-09-30Cons.Net assets
Net assets / equity¥138.3bnat 2022-03-31Cons.Net assets
Net assets / equity¥138.3bnat 2021-09-30Cons.Net assets (5-year summary)
Cash and deposits¥60.8bnat 2022-09-30Cons.Cash and deposits
Cash and deposits¥61.0bnat 2022-03-31Cons.Cash and deposits
Cash & equivalents¥75.5bnat 2022-09-30Cons.Cash and cash equivalents
Cash & equivalents¥74.6bnat 2022-03-31Cons.Cash and cash equivalents
Cash & equivalents¥76.3bnat 2021-09-30Cons.Cash and cash equivalents
Cash & equivalents¥77.3bnat 2021-03-31dCons.Cash and cash equivalents
Operating cash flow¥6.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥13.3bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥5.4bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥1.4bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥7.9bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.2bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥4.2bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥8.1bn2021-04-01 → 2022-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow−¥5.3bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥158.342022-04-01 → 2022-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥81.452022-07-01 → 2022-09-30dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥251.432021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥176.242021-04-01 → 2021-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥88.452021-07-01 → 2021-09-30dCons.Basic earnings loss per share (5-year summary)
Equity ratio83.6%at 2022-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio83.4%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio83.5%at 2021-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 18
SegmentItemPeriodValue
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue2022-04-01 → 2022-09-30¥35.6bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue external2022-04-01 → 2022-09-30¥35.6bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentsegment profit2022-04-01 → 2022-09-30¥7.6bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue2022-04-01 → 2022-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue external2022-04-01 → 2022-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentsegment profit2022-04-01 → 2022-09-30¥616m
Total Of Reportable Segments And Otherssegment totalrevenue2022-04-01 → 2022-09-30¥36.8bn
Total Of Reportable Segments And Otherssegment totalrevenue external2022-04-01 → 2022-09-30¥36.8bn
Total Of Reportable Segments And Otherssegment totalsegment profit2022-04-01 → 2022-09-30¥8.2bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue2021-04-01 → 2021-09-30¥36.4bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentrevenue external2021-04-01 → 2021-09-30¥36.4bn
jpcrp040300-q2r_E00935-000Medicinereportable segmentsegment profit2021-04-01 → 2021-09-30¥8.4bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue2021-04-01 → 2021-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentrevenue external2021-04-01 → 2021-09-30¥1.2bn
jpcrp040300-q2r_E00935-000Real Estatereportable segmentsegment profit2021-04-01 → 2021-09-30¥635m
Total Of Reportable Segments And Otherssegment totalrevenue2021-04-01 → 2021-09-30¥37.6bn
Total Of Reportable Segments And Otherssegment totalrevenue external2021-04-01 → 2021-09-30¥37.6bn
Total Of Reportable Segments And Otherssegment totalsegment profit2021-04-01 → 2021-09-30¥9.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 464
ItemContextValueUnit
Other nclPrior1YearInstant431000000JPY
Other nclCurrentQuarterInstant443000000JPY
Noncurrent liabilitiesPrior1YearInstant7806000000JPY
Noncurrent liabilitiesCurrentQuarterInstant7688000000JPY
LiabilitiesPrior1YearInstant26855000000JPY
LiabilitiesCurrentQuarterInstant26922000000JPY
Capital stockPrior1YearInstant23853000000JPY
Capital stockCurrentQuarterInstant23853000000JPY
Capital surplusPrior1YearInstant11406000000JPY
Capital surplusCurrentQuarterInstant11406000000JPY
Retained earningsPrior1YearInstant126347000000JPY
Retained earningsCurrentQuarterInstant129472000000JPY
Treasury stockPrior1YearInstant-28714000000JPY
Treasury stockCurrentQuarterInstant-30025000000JPY
Shareholders equityPrior1YearInstant132893000000JPY
Shareholders equityCurrentQuarterInstant134707000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant4551000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant4765000000JPY
Remeasurements of defined benefit plansPrior1YearInstant301000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant333000000JPY
Valuation and translation adjustmentsPrior1YearInstant4853000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant5099000000JPY
Non controlling interestsPrior1YearInstant578000000JPY
Non controlling interestsCurrentQuarterInstant578000000JPY
Net assetsPrior1YearInstant138325000000JPY
Net assetsCurrentQuarterInstant140384000000JPY
Liabilities and net assetsPrior1YearInstant165181000000JPY
Liabilities and net assetsCurrentQuarterInstant167307000000JPY
Net salesPrior1YTDDuration37588000000JPY
Net salesCurrentYTDDuration36819000000JPY
Cost of salesPrior1YTDDuration16588000000JPY
Cost of salesCurrentYTDDuration16432000000JPY
Gross profitPrior1YTDDuration20999000000JPY
Gross profitCurrentYTDDuration20387000000JPY
Salaries sgaPrior1YTDDuration2877000000JPY
Salaries sgaCurrentYTDDuration2815000000JPY
Bonuses and provision for bonuses sgaPrior1YTDDuration640000000JPY
Bonuses and provision for bonuses sgaCurrentYTDDuration606000000JPY
Retirement benefit expenses sgaPrior1YTDDuration187000000JPY
Retirement benefit expenses sgaCurrentYTDDuration170000000JPY
Research and development expenses sgaPrior1YTDDuration4008000000JPY
Research and development expenses sgaCurrentYTDDuration4330000000JPY
Other sgaPrior1YTDDuration4248000000JPY
Other sgaCurrentYTDDuration4255000000JPY
Selling general and administrative expensesPrior1YTDDuration11963000000JPY
Selling general and administrative expensesCurrentYTDDuration12178000000JPY
Operating incomePrior1YTDDuration9036000000JPY
Operating incomeCurrentYTDDuration8209000000JPY
Interest income noiPrior1YTDDuration3000000JPY
Interest income noiCurrentYTDDuration3000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass